Article Versions Notes

Fiedler S, Ambros IM, Glogova E, Benesch M, Urban C, Mayer M, Ebetsberger-Dachs G, Bardi E, Jones N, Gamper A, et al. Long-Term Outcome and Role of Biology within Risk-Adapted Treatment Strategies: The Austrian Neuroblastoma Trial A-NB94. Cancers. 2021; 13(3):572. https://doi.org/10.3390/cancers13030572

Fiedler, Stefan, Inge M. Ambros, Evgenia Glogova, Martin Benesch, Christian Urban, Marlene Mayer, Georg Ebetsberger-Dachs, Edit Bardi, Neil Jones, Agnes Gamper, and et al. 2021. "Long-Term Outcome and Role of Biology within Risk-Adapted Treatment Strategies: The Austrian Neuroblastoma Trial A-NB94" Cancers 13, no. 3: 572. https://doi.org/10.3390/cancers13030572

Fiedler, S., Ambros, I. M., Glogova, E., Benesch, M., Urban, C., Mayer, M., Ebetsberger-Dachs, G., Bardi, E., Jones, N., Gamper, A., Meister, B., Crazzolara, R., Amann, G., Dieckmann, K., Horcher, E., Kerbl, R., Brunner-Herglotz, B., Ziegler, A., Ambros, P. F., & Ladenstein, R. (2021). Long-Term Outcome and Role of Biology within Risk-Adapted Treatment Strategies: The Austrian Neuroblastoma Trial A-NB94. Cancers, 13(3), 572. https://doi.org/10.3390/cancers13030572